Slide 1: Presentation for investors, analysts and media
Presentation for investors, analysts and media Basel, August 13, 2025
Slide 2: Forward-looking statements
This presentation contains forward-looking statements, including statements regarding the beliefs, expectations and assumptions of future results, performance or achievements of Straumann Group, that are based upon information available to Straumann Group as of the date such statements are made. For
Slide 3: Highlights, Financials, Strategy, Outlook, Q&A
Highlights Guillaume Daniellot Financials Isabelle Adelt Recent achievements & strategy Guillaume Daniellot Outlook 2025 Guillaume Daniellot Q&A Guillaume Daniellot, Isabelle Adelt 3
Slide 4: Highlights
HIGHLIGHTS Guillaume Daniellot, CEO
Slide 5: H1 2025 highlights
Revenue in H1 20251 Organic revenue growth in H1 20251 EBIT margin at constant currency3 1.3 bn 10.2% 27.3% CHF 667.5 m revenue in Q2 or 5.9% in CHF and Core EBIT margin 26.6% including strong 9.3% organic growth2 in Q2 currency headwinds or 1.9% in CHF Innovation Localized production Outlook 2025 c
Slide 6: Regional organic growth Q2 2025
EMEA NAM Q2 8.2% Q2 24 12.4% Q2 2.7% Q2 24 5.3% 40 %* 26 %* GROUP APAC 25 %* 9 %* LATAM Q2 16.4% Q2 24 33.8% Q2 16.2% Q4 24 14.9% 6 * % of Q2 2025 Group total revenue
Slide 7: Isabelle Adelt, CFO
Isabelle Adelt, CFO 7
Slide 8: Change in organic growth
Regional % share of organic growth +1.9% +9.3% Organic 8 668 8 NAM 24 655 LATAM 14 5 20 36 EMEA 611 -44 0 Change in organic growth 42 APAC +8.2% +2.7% +16.4% +16.2% Revenue FX effect M&A effect Adjusted EMEA NAM APAC LATAM Revenue Q2 2025 Q2 2024 Revenue base Q2 2025 8
Slide 9: Gross profit margin bridge
in %, rounded +10 bps 72.1 0.4 72.0 0.6 72.1 71.9 -0.5 -0.5 -0.2 IFRS Gross Non-Core FX effect Core Gross Mix, Productivity Shanghai Core Gross Non-Core IFRS Gross Profit Margin items Profit Margin & Others campus Profit Margin items Profit Margin HY1 2024 HY1 2024 ramp-up HY1 2025 HY1 2025 @FX 2024
Slide 10: EBIT margin bridge
in %, rounded -40 bps 1.4 0.8 -1.1 26.4 26.9 -0.1 26.6 -0.9 0.1 24.4 -2.2 IFRS EBIT Non-core FX effect Core EBIT Gross Profit Distribution Administration Other Core EBIT Non-Core IFRS EBIT Margin items Margin Margin expense expense Margin items Margin HY1 2024 HY1 2024 change HY1 2025 HY1 2025 @FX 2
Slide 11: Free Cashflow
Free Cashflow1 CHF 113m (8.4% of Net Revenue) in H1 2025 -34.3% 219 375 -156 247 -191 Cash Net Cash Net Cash Net Cash Cash 1 Jan 2025 Operating Investing Financing & FX on Cash 30 Jun 2025 11 1 Continuing operations
Slide 12: HY1 2025 income statement
HY1 20251 % of Revenue CER Change in %2 CER Margin Change2 REVENUE 1 348 10.2% COGS -376 27.9% GROSS PROFIT 972 72.1% 10.3% +10 bps Operating expenses -619 45.9% Other Result 5 0.4% EBIT 358 26.6% 8.7% -40 bps EBIT Margin at 20243 27.3% -30 bps Financial result -24 1.8% Associates -9 0.7% Income tax
Slide 13: Guillaume Daniellot, CEO
Guillaume Daniellot, CEO 13 CONFIDENTIAL/INTERNAL USE ONLY
Slide 14: Market size and market share
6 5.6 4.7 Market size in CHF bn 2.6 Market 35% 0.7 share % 35% ~15% ~3% >5% <5% Implantology Regeneratives ClearAligner CADCAM CADCAM equipment prosthetics Straumann Group share within the 12.5% 14 Source: Straumann Group estimates addressable market in 2024
Slide 15: Innovation, Digitalization, Education
Innovation Digitalization Education 15
Slide 16: Suited for immediacy
Suited for immediacy hard bone bone density bone 16
Slide 17: BLC TLC BLX implants
BLC TLC BLX TLX SLActive advanced surface technology supports osseointegration faster Roxolid helps reduce invasiveness and treatment complexity SLA® SLA is a proven surface technology that NEW promotes reliable bone integration for • Ø3.75, Ø5.5 and Ø6.5 options for wide molars standard healing pro
Slide 18: World's first two-piece ceramic implant system
• World’s first two-piece ceramic implant system Distinct biological advantages of using proprietary ceramic implants ceramic injection • Reduced risk of inflammation molding • Improved soft tissue integration • Studies suggest a lower • Scalable production incidence of peri-implantitis processes en
Slide 19: Place Scan Restore
Place 1 Immediate socket seal Scan 2 Without removing Restore 3 100% matching emergence profile 19
Slide 20: STRAUMANN SIRIOS and coDiagnostiX
STRAUMANN STRAUMANN coDiagnostiX SIRIOS EXACT 20
Slide 21: Clinical education & training center
Clinical education & training center Significant underpenetrated market – education investment is key to unlocking growth Significant progress with local manufacturing First implant product license in June 2025 21
Slide 22: Our culture - the catalyst for long-term performance
OUR CULTURE - THE CATALYST FOR LONG-TERM PERFORMANCE THE SMILE straumanngroup FOUNDATION
Slide 23: Growth ambition 2030 confirmed
Market environment Revenue and profitability and assumption • Uncertain economic environment remains • Organic revenue growth in the high single-digit • Group believes global patient flow should remain percentage range stable • With 30 to 60 basis points improvement of the • Continue to outgrow mark
Slide 24: Confidential / Internal use only
24 CONFIDENTIAL/INTERNAL USE ONLY
Slide 25: 25
25
Slide 26: Investor events 2025
2025 Event Location August 14 – 15 Swiss Roadshow Zurich & Geneva September 3 Wells Fargo Healthcare Conference Boston September 4 Goldman Sachs Medtech Conference London September 8 Morgan Stanley Healthcare Conference New York September 9 – 10 Canada Roadshow Toronto & Montreal September 23 UBS Co
Slide 27: IFRS to Core reconciliation
(in CHF 1 000) IFRS M&A Impairments Restructuring Legal cases Associates1 CORE Revenue 1 348 199 1348 199 Cost of goods sold (379 340) 62 3 124 (376 154) Gross profit 968 860 62 3 124 972 046 Other income 4 382 419 4 801 Distribution expense (247 397) 3 099 2 255 (242 043) Administrative expense (39
Slide 28: HY1 2025 IFRS income statement
HY1 20251 % of Revenue CER Change in %2 CER Margin Change2 REVENUE 1 348 10.2% COGS -379 28.1% GROSS PROFIT 969 71.9% 10.5% +20 bps Operating expenses -643 47.7% Other Result 4 0.3% EBIT 330 24.4% 5.9% -100 bps Financial result -28 2.1% Associates -9 0.7% Income tax -54 4.0% NET PROFIT (from continu
Slide 29: Revenue and cost breakdown, exchange rates
Revenue breakdown H1 2025 Exchange rates development 2023 – 2025 110.00 CHF Other 1.4% EUR 100.00 21.0% 25.6% BRL 90.00 5.8% CNY 80.00 16.3% USD/CAD/AUD 70.00 30.0% 06/2023 09/2023 12/2023 03/2024 06/2024 09/2024 12/2024 03/2025 06/2025 Total cost breakdown H1 2025 USDCHF EURCHF CNYCHF BRLCHF Other
Slide 30: Thank you
THANK YOU 30